Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
KALA Bio is a biopharmaceutical company focused on developing innovative, cell-free therapies for rare and severe eye diseases. Its lead candidate, KPI-012, targets persistent corneal epithelial defects, leveraging mesenchymal stem cell secretome technology. The company advances clinical trials, seeks regulatory approval, and explores platform applications for other ocular conditions, aiming to improve healing and vision preservation through proprietary biologic solutions.
This description was generated via AI from an annual report. Updated about 1 year ago.